Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …

Experimental evidence accumulated over decades has implicated epithelial–mesenchymal
plasticity (EMP), which collectively encompasses epithelial–mesenchymal transition and the …

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …

Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …

Introduction Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Recent years have …

Objective Hepatocellular carcinoma (HCC) is heterogeneous, especially in multifocal
tumours, which decreases the efficacy of clinical treatments. Understanding tumour …

Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide and
available therapies, including immunotherapies, are ineffective for many patients. HCC is …

Introduction Hepatocellular carcinoma (HCC) represents the sixth most commonly
diagnosed malignancy worldwide, accounting for millions of deaths annually. Despite …

Thermal ablative therapies are standard treatments for localized hepatocellular carcinoma
(HCC). In addition to local tumor destruction, ablation leads to abscopal effects in distant …

Immunotherapy is a promising approach to treating various types of cancers, including
hepatocellular carcinoma (HCC). While single immunotherapy drugs show limited …